Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,dividendsPaid,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingAnnualDividendYield,priceHint,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchangeDataDelayedBy,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,HLTRF,-76907000.0,31822400,,,-2020000,,-2197000,5987000,12548000,-510000,-510000,,-1703000,,,,177000,14945000,15455000,2397000,-1510000,,-2197000,-2197000,246737000.0,11474000.0,126274000.0,169830000.0,6585000.0,296104000.0,263275000.0,-111119000.0,1536000.0,6200000.0,908000.0,21347000.0,33634000.0,908000.0,11250000.0,6200000.0,1172000.0,47287000.0,12867000.0,90551000.0,10063000.0,15321000.0,,-146000.0,-2532000.0,-2412000.0,-1083000.0,-1343000.0,2639000.0,-1856000.0,44000.0,1715000.0,7480000.0,-1310000.0,327000.0,-1573000.0,-552000.0,-9000.0,,13653000.0,en-US,US,EQUITY,False,Delayed Quote,USD,14.45,1630505111,-0.4420004,14.45,14.45,14.45,503,-2.9680393,14.45 - 14.45,14.892,finmb_303684187,Other OTC,HLS Therapeutics Inc.,USD,86,318,4.3005,0.42371544,10.1495 - 16.9857,-2.5357008,-0.14928444,10.1495,16.9857,1639526400,1620304200,1635942600,1636374600,0.161,0.010811173,2,PNK,-0.637,5.234,14.096075,0.35392475,0.025108036,14.825795,-0.37579536,-0.0253474,459833664,2.7607946,15,America/New_York,EDT,-14400000,False,False,0,HLS THERAPEUTICS INC,us_market,PRE,0.68,,,16.99,10.15,14.1,14.83,86,318,31.82M,,11.27M,7.14%,62.69%,,,,,,0.16,1.11%,0.16,1.08%,,,"Dec 14, 2021","Oct 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",-27.11%,-15.31%,-1.92%,-9.43%,58.87M,1.85,18.60%,47.02M,21.78M,-15.96M,-0.64,,21.35M,0.66,102.83M,60.55,1.41,5.23,17.11M,-24.43M,Value,M9W 6L2,Healthcare,88,5,8,"HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.",Toronto,647 495 9000,ON,6,1609372800,1625097600,7,Canada,http://www.hlstherapeutics.com,86400,7,10 Carlson Court,416 213 0045,Drug Manufacturers—Specialty & Generic,Suite 701
t-1,HLTRF,-80154000.0,31822400,,,-4479000,,-4753000,5539000,12207000,-3046000,-3046000,,-1606000,,,,274000,14314000,17360000,2107000,-1433000,,-4753000,-4753000,247612000.0,11772000.0,129274000.0,167458000.0,7964000.0,296732000.0,259825000.0,-107602000.0,218000.0,3463000.0,967000.0,23203000.0,35096000.0,967000.0,10500000.0,3463000.0,1263000.0,46890000.0,11135000.0,93380000.0,10205000.0,16126000.0,,181000.0,-1354000.0,-2405000.0,-3260000.0,164000.0,412000.0,2591000.0,20000.0,7185000.0,7367000.0,-1267000.0,525000.0,1425000.0,2428000.0,-6000.0,,11794000.0,en-US,US,EQUITY,False,Delayed Quote,USD,14.45,1630505111,-0.4420004,14.45,14.45,14.45,503,-2.9680393,14.45 - 14.45,14.892,finmb_303684187,Other OTC,HLS Therapeutics Inc.,USD,86,318,4.3005,0.42371544,10.1495 - 16.9857,-2.5357008,-0.14928444,10.1495,16.9857,1639526400,1620304200,1635942600,1636374600,0.161,0.010811173,2,PNK,-0.637,5.234,14.096075,0.35392475,0.025108036,14.825795,-0.37579536,-0.0253474,459833664,2.7607946,15,America/New_York,EDT,-14400000,False,False,0,HLS THERAPEUTICS INC,us_market,PRE,0.68,,,16.99,10.15,14.1,14.83,86,318,31.82M,,11.27M,7.14%,62.69%,,,,,,0.16,1.11%,0.16,1.08%,,,"Dec 14, 2021","Oct 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",-27.11%,-15.31%,-1.92%,-9.43%,58.87M,1.85,18.60%,47.02M,21.78M,-15.96M,-0.64,,21.35M,0.66,102.83M,60.55,1.41,5.23,17.11M,-24.43M,Value,M9W 6L2,Healthcare,88,5,8,"HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.",Toronto,647 495 9000,ON,6,1609372800,1625097600,7,Canada,http://www.hlstherapeutics.com,86400,7,10 Carlson Court,416 213 0045,Drug Manufacturers—Specialty & Generic,Suite 701
t-2,HLTRF,-84155000.0,31822400,,,-6721000,,-7278000,5663000,13890000,-3706000,-3706000,,-1831000,,,,557000,16485000,20191000,2595000,-3015000,,-7278000,-7278000,253404000.0,11393000.0,134657000.0,169249000.0,8691000.0,303906000.0,257411000.0,-101575000.0,,2020000.0,3207000.0,20612000.0,35642000.0,1173000.0,12336000.0,2020000.0,1384000.0,45911000.0,12497000.0,98239000.0,10630000.0,14223000.0,,-2068000.0,-2822000.0,-2408000.0,-3646000.0,-285000.0,412000.0,-278000.0,344000.0,5846000.0,9513000.0,-1238000.0,1036000.0,363000.0,4192000.0,-4000.0,,10269000.0,en-US,US,EQUITY,False,Delayed Quote,USD,14.45,1630505111,-0.4420004,14.45,14.45,14.45,503,-2.9680393,14.45 - 14.45,14.892,finmb_303684187,Other OTC,HLS Therapeutics Inc.,USD,86,318,4.3005,0.42371544,10.1495 - 16.9857,-2.5357008,-0.14928444,10.1495,16.9857,1639526400,1620304200,1635942600,1636374600,0.161,0.010811173,2,PNK,-0.637,5.234,14.096075,0.35392475,0.025108036,14.825795,-0.37579536,-0.0253474,459833664,2.7607946,15,America/New_York,EDT,-14400000,False,False,0,HLS THERAPEUTICS INC,us_market,PRE,0.68,,,16.99,10.15,14.1,14.83,86,318,31.82M,,11.27M,7.14%,62.69%,,,,,,0.16,1.11%,0.16,1.08%,,,"Dec 14, 2021","Oct 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",-27.11%,-15.31%,-1.92%,-9.43%,58.87M,1.85,18.60%,47.02M,21.78M,-15.96M,-0.64,,21.35M,0.66,102.83M,60.55,1.41,5.23,17.11M,-24.43M,Value,M9W 6L2,Healthcare,88,5,8,"HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.",Toronto,647 495 9000,ON,6,1609372800,1625097600,7,Canada,http://www.hlstherapeutics.com,86400,7,10 Carlson Court,416 213 0045,Drug Manufacturers—Specialty & Generic,Suite 701
t-3,HLTRF,-85862000.0,31822400,,,-1481000,,-1733000,6547000,11067000,-1753000,-1753000,,-1428000,,,,252000,13129000,14882000,2062000,272000,,-1733000,-1733000,254705000.0,10972000.0,137149000.0,168843000.0,11522000.0,305992000.0,256292000.0,-93056000.0,,-5365000.0,3029000.0,20890000.0,35428000.0,1042000.0,9000000.0,-5365000.0,1328000.0,46930000.0,12535000.0,101014000.0,11146000.0,14565000.0,104000.0,-979000.0,-32669000.0,18620000.0,16944000.0,101000.0,7000.0,-12772000.0,588000.0,2365000.0,6916000.0,-1201000.0,86000.0,129000.0,-2199000.0,-5000.0,-482000.0,11502000.0,en-US,US,EQUITY,False,Delayed Quote,USD,14.45,1630505111,-0.4420004,14.45,14.45,14.45,503,-2.9680393,14.45 - 14.45,14.892,finmb_303684187,Other OTC,HLS Therapeutics Inc.,USD,86,318,4.3005,0.42371544,10.1495 - 16.9857,-2.5357008,-0.14928444,10.1495,16.9857,1639526400,1620304200,1635942600,1636374600,0.161,0.010811173,2,PNK,-0.637,5.234,14.096075,0.35392475,0.025108036,14.825795,-0.37579536,-0.0253474,459833664,2.7607946,15,America/New_York,EDT,-14400000,False,False,0,HLS THERAPEUTICS INC,us_market,PRE,0.68,,,16.99,10.15,14.1,14.83,86,318,31.82M,,11.27M,7.14%,62.69%,,,,,,0.16,1.11%,0.16,1.08%,,,"Dec 14, 2021","Oct 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",-27.11%,-15.31%,-1.92%,-9.43%,58.87M,1.85,18.60%,47.02M,21.78M,-15.96M,-0.64,,21.35M,0.66,102.83M,60.55,1.41,5.23,17.11M,-24.43M,Value,M9W 6L2,Healthcare,88,5,8,"HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.",Toronto,647 495 9000,ON,6,1609372800,1625097600,7,Canada,http://www.hlstherapeutics.com,86400,7,10 Carlson Court,416 213 0045,Drug Manufacturers—Specialty & Generic,Suite 701
